Skip to main content

Table 1 Data sources for estimating costs

From: Real-world costs of autosomal dominant polycystic kidney disease in the Nordics

Type of data

Country

Source

Direct costsa

Denmark

Danish Medicines Agency [13]

Statens Serum Institut [14]

The Capital Region of Denmark [15]

Rigshospitalet [16]

Finland

Pharmaceuticals Pricing Board [17]

The Social Insurance Institution of Finland [18]

The Hospital District of Helsinki and Uusimaa [19, 20]

National institute for health and welfare [21]

Kuopio University Hospital [22]

Norway

Norwegian Medicines Agency [23]

Norwegian Directorate of Health [24, 25]

Ministry of Health and Care Services [26]

Sweden

Dental and Pharmaceutical Benefits Agency [27]

Swedish Association of the Pharmaceutical Industry [12]

Region Skåne [28]

Stockholm County Council [29]

Indirect costs

Denmark

Statistics Denmark [30, 31]

Eurostat [32]

KPMG [33]

Finland

Statistics Finland [34, 35]

Norway

Statistics Norway [36,37,38]

KPMG [33]

Sweden

Statistics Sweden [39, 40]

Swedish Tax Agency [41]

  1. aTransportation costs (to and from haemodialysis) were based on answers in the self-administered questionnaire: taxi, 15 km; public transport, 30 min duration; car, 30 km